Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Meat and Whey Protein Supplementation in Endurance Athletes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02954367
Recruitment Status : Unknown
Verified November 2016 by DIEGO MORENO PÉREZ, Universidad Europea de Madrid.
Recruitment status was:  Active, not recruiting
First Posted : November 3, 2016
Last Update Posted : November 3, 2016
Sponsor:
Collaborator:
University of Greenwich
Information provided by (Responsible Party):
DIEGO MORENO PÉREZ, Universidad Europea de Madrid

Brief Summary:
The aim of this project is to investigate the potential benefits of combining a new protein meat hydrolysates extract with a regular endurance training programme on (a) body composition (b) performance (c) muscle structure (d) immunology and (e) microbiota (f) haematological markers in endurance athletes

Condition or disease Intervention/treatment Phase
Dietary Modification Dietary Supplement: PROTEIN Dietary Supplement: CARBOHYDRATE Not Applicable

  Hide Detailed Description

Detailed Description:

PROYECT DESIGN This investigation involves a 10-week randomised, balanced, double blind parallel group between-subjects design, aimed to analyse the effects of combining endurance exercise and a post exercise nutrition strategy (hydrolysates meat protein (MEAT) + whey protein (W) or a isocaloric only carbohydrate placebo) on training outcomes, immunity and haematological variables after regular training and feeding intervention.

Participants will be divided in two-treatment groups 1) Hydrolysed meat-protein + whey (PROT); and 2) non-protein iso-energetic placebo (CHO). Once considered eligible for the study, and after an initial familiarisation period plus baseline tests (endurance performance body composition and blood extractions) participants will be randomly assigned to one of the intervention groups: PROT and CHO. Each group will follow a 10-week periodised endurance training intervention combined with one of the two specific supplementation treatments (PROT or CHO). Measurements of performance (VO2peak, vetilatory threshold and time to exhaustion at maximal aerobic intensity), body composition (fat and fat free mass), microbiota and haematology will be determined before and after the 10-week intervention period.

Once informed consent and health history have been obtained, after the baseline assessment (t1), participants will be divided into two similar profile groups, matched by body mass, age, sex and maximal oxygen uptake (VO2peak): (1) PROT (2) CHO

INTERVENTION The intervention will comprise of a 10-week combined supplementation (MEAT + W and CHO) regular endurance-training programme.

Endurance training Participants will commit to follow a polarised triphasic endurance-training model. This model contains three intensity zones calculated as low intensity [< the first ventilatory threshold (VT1), ~ 70% HRmax]; moderate intensity [between VT1 and respiratory compensation point or ventilatory threshold 2 (VT2), >70 < 90% HRmax]; and high intensity [>VT2, 90% HRmax]. Participants will train 5 to 6 times per week with a total percentage distribution of 75 to 80% at low intensity; 10% at moderate intensity, and 15 to 10% at high intensity.

Cardiorespiratory test Participants will perform a maximal cardiorespiratory exercise test before the training period to determine peak oxygen uptake (VO2peak) and ventilatory thresholds. Percentage of HRmax and the 15 points (6 to 20) Borg Scale Rate of Perceive Exertion (RPE) will be used to appropriately select the load along the training intervention.

Supplementation protocol Training days: Immediately (<10 min) after completing each training session, participants will consume a beverage containing 20g of supplement (10g MEAT + 10g W) plus 200 ml of orange juice or only carbohydrate placebo (maltodextrine and orange juice).

Non-training days: before breakfast.

Supplements and placebo will be provided in powder form and should be mixed with 200ml of orange juice and water at the moment of consumption.

The supplements and placebo will look and taste identical.

Thus a total of one 20g doses will be administered on a daily base. Participants are required to ingest a total of 70 for the total of 10 weeks of the study intervention.

Supplements will be provided in 14 days intervals and distributed by a blinded researcher after participants return the empty bag of the supplement/placebo consumed during the previous 14 day period.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 44 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effects of Meat Protein Administration on Body Composition, Strength, Immunological, Microbiota and Haematological Markers in Endurance Athletes
Study Start Date : April 2016
Estimated Primary Completion Date : April 2017

Arm Intervention/treatment
Experimental: PROTEIN (MEAT + WHEY)
Post workout (training days) or breakfast (non training days) 20g of meat protein (10g meat + 10g whey) mixed with 200ml of orange juice and water
Dietary Supplement: PROTEIN
Immediately (<10 min) after completing each training session (resistance training) participants will consume a beverage containing 20g of meat protein (10g) plus whey (10g) mixed with 200 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
Other Name: 100% BEEF

Placebo Comparator: CARBOHYDRATE (CHO)
Post workout (training days) or breakfast (non training days) 20g of maltodextrin mixed with 200ml orange juice and water
Dietary Supplement: CARBOHYDRATE
Immediately (<10 min) after completing each training session (resistance training), participants will consume a beverage containing about 20g of maltodextrin mixed with 200 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
Other Name: Maltodextrin




Primary Outcome Measures :
  1. % Fat Mass (Body composition) [ Time Frame: 10 weeks ]
    Estimated with Densitometry (DEXA)

  2. Visceral Adipose Tissue Mass (g) (Body composition) [ Time Frame: 10 weeks ]
    Estimated with DEXA

  3. Total Fat Free mass (g) (Body composition) [ Time Frame: 10 weeks ]
    Estimated with DEXA

  4. Bone mineral density (g/cm3) (Body composition) [ Time Frame: 10 weeks ]
    Estimated with DEXA


Secondary Outcome Measures :
  1. Blood Glucose (mg/dl) [ Time Frame: 10 weeks ]
  2. Creatine Kinase (Ul/l) -Blood markers- [ Time Frame: 10 weeks ]
  3. Creatinine (mg/dl) - Blood markers - [ Time Frame: 10 weeks ]
  4. Myoglobin (ng/ml) - Blood markers - [ Time Frame: 10 weeks ]
  5. Total cholesterol (mg/dl) -Blood markers- [ Time Frame: 10 weeks ]
  6. HDL cholesterol (mg/dl) -Blood markers- [ Time Frame: 10 weeks ]
  7. LDL cholesterol (mg/dl) -Blood markers- [ Time Frame: 10 weeks ]
  8. Aspartate amino transferasa (Ul/l) -Blood markers- [ Time Frame: 10 weeks ]
  9. Triglycerides (mg/dl) -Blood markers- [ Time Frame: 10 weeks ]
  10. Hemoglobin (g/dl) -Blood markers- [ Time Frame: 10 weeks ]
  11. Erythrocyte (M/µL) -Blood markers- [ Time Frame: 10 weeks ]
  12. Haematocrit (%) -Blood markers- [ Time Frame: 10 weeks ]
  13. Mean corpuscular volume (cubic millimeter)-Blood markers- [ Time Frame: 10 weeks ]
  14. Serum Transferrin (mg/dl) -Blood markers- [ Time Frame: 10 weeks ]
  15. Transferrin saturation (%) -Blood markers- [ Time Frame: 10 weeks ]
  16. Neutrophils (%) -Blood markers- [ Time Frame: 10 weeks ]
  17. Lymphocyte (%) -Blood markers- [ Time Frame: 10 weeks ]
  18. Monocytes (%) -Blood markers- [ Time Frame: 10 weeks ]
  19. Ferritin, serum (ng/ml) -Blood markers- [ Time Frame: 10 weeks ]
  20. Progressive maximal oxygen consumption test (Cardiorespiratory test) [ Time Frame: 10 weeks ]
    - Maximum oxygen uptake (ml/kg/min)

  21. Time to exhaustion at maximal aerobic (min) [ Time Frame: 10 weeks ]
  22. Gut microbiota determination by 16S rRNA Sequencing [ Time Frame: 10 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 18 years to 45
  • Vo2max >50ml/kg/min
  • Regularly trained athletes,
  • Minimum 3 years of experience in resistance training exercise,
  • Volunteers,

Exclusion Criteria:

  • any musculoskeletal injuries, metabolic conditions, or diseases;
  • use of medications, smoking, and nutritional supplements known to affect physical performance, muscle damage or recovery process (e.g., creatine, whey protein, and amino acids) within 6 weeks prior to the start of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02954367


Sponsors and Collaborators
Universidad Europea de Madrid
University of Greenwich
Investigators
Layout table for investigator information
Principal Investigator: DIEGO MORENO, PhD Universidad Europea de Madrid
Principal Investigator: FERNANDO NACLERIO, PhD University of Greenwich

Layout table for additonal information
Responsible Party: DIEGO MORENO PÉREZ, PhD, Universidad Europea de Madrid
ClinicalTrials.gov Identifier: NCT02954367     History of Changes
Other Study ID Numbers: BEEF-UEM-01
First Posted: November 3, 2016    Key Record Dates
Last Update Posted: November 3, 2016
Last Verified: November 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No